RxDoctor Payments Data

Bowei Tan, MD

Hospitalist · Montgomery, ALNPI 1477936086

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Johnson & Johnson at 24.3% of the total. Reporting peaked in 2022 at $439 and has fallen 94.3% since, to $25 in 2025. Among hospitalist clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,014in general payments, 2019–2025

Across 96 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$489
  • Novartis$436
  • Pfizer$270
  • AbbVie$157
  • E.r. Squibb & Sons, L.L.C.$103
  • Boehringer Ingelheim$98
  • plus $462 from 11 others

What the payments were for

  • Food & beverage$2,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,014 in reported general payments places this provider in the 90th percentile of 265 hospitalist providers in Alabama.

See all hospitalist providers in Alabama

Medicare billing

Part B allowed, 2024
$87,493
Medicare patients
276
Services billed
783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$42,306
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,996
Amiodarone Hcl36$399
Metoprolol Succinate27$302
Albuterol Sulfate HfaAlbuterol Sulfate12$270
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$254
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$206
Atorvastatin Calcium19$181
Cefdinir22$161
Hydralazine Hcl17$160
Spironolactone11$151
Amlodipine Besylate34$131
Methylprednisolone17$123
Losartan Potassium13$121
ClopidogrelClopidogrel Bisulfate13$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$270$42,30642 claims
GSKTrelegy Ellipta$16$14,99622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 hospitalist providers in Alabama.

Other hospitalist in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →